NCT
Number |
Title |
Conditions |
Interventions |
Sponsor
/Collaborators |
Phases |
NCT03240822 |
Human Penile Tissue Allotransplantation for Devastating Penile and Concomitant Genital Trauma |
Urologic Injuries
Genital Diseases, Male
Amputation |
Procedure: Penile Transplant
Biological:
Monoclonal Antibody
(Humanized Anti-CD52)
Drug: Tacrolimus |
Anthony Atala
Wake Forest University Health Sciences |
Phase 1 |
NCT03239899 |
PD-1 Inhibition to Determine CNS Reservoir of HIV-Infection |
HIV Infections |
Drug: Pembrolizumab |
National Institute of Neurological Disorders and Stroke (NINDS)
National Institutes of Health Clinical Center (CC) |
Phase 1 |
NCT03237780 |
Atezolizumab With or Without Eribulin Mesylate in Treating Patients With Recurrent Locally Advanced or Metastatic Urothelial Cancer |
Metastatic Urothelial Carcinoma
Recurrent Bladder Urothelial Carcinoma... |
Drug: Atezolizumab
Drug: Eribulin Mesylate
Other: Laboratory
Biomarker Analysis |
National Cancer Institute (NCI) |
Phase 2 |
NCT03239470 |
Polyclonal Regulatory T Cells (PolyTregs) for Pemphigus |
Pemphigus Foliaceus
Pemphigus Vulgaris |
Biological: Cohort 1:
2.5 x 10^8 PolyTregs
Biological:
Cohort 2:
10x10^8 PolyTregs |
National Institute of Allergy and Infectious Diseases (NIAID)
Autoimmunity Centers of Excellence |
Phase 1 |
NCT03241173 |
A Study Exploring the Safety and Efficacy of INCAGN01949 in Combination With Immune Therapies in Advanced or Metastatic Malignancies |
Advanced or Metastatic Malignancies |
Drug: INCAGN01949
Drug: Nivolumab
Drug: Ipilimumab |
Incyte Corporation |
Phase 1
Phase 2 |